NIH ends trial of Eli Lilly COVID-19 antibody treatment among hospitalized patients

Peter Weber, The Week US's avatar
By
published
Eli Lilly research facility.
(Image credit: jetcityimage/iStock)

The U.S. National Institutes of Health on Monday ended one clinical trial of Eli Lilly's experimental COVID-19 antibody treatment after finding that the drug, "bamlanivimab, is unlikely to help hospitalized COVID-19 patients recover from this advanced stage of their disease." The trial was suspended Oct. 13 out of "an abundance of caution," but the NIH said Monday it had found no significant safety issue with the monoclonal antibody treatment.

Eli Lilly said it will continue testing bamlanivimab with the NIH on mild or moderately ill COVID-19 patients to see if it reduces hospitalizations and severe symptoms. Eli Lilly is also conducting its own separate trials.

Human bodies make antibodies to fight off infections, and Eli Lilly's experimental drug, like a similar treatment from Regeneron, features concentrated copies of one or two antibodies found to be effective at fighting of COVID-19. President Trump was given Regeneron's version when he was hospitalized with COVID-19, and public health experts have high hopes for monoclonal antibody treatments. Eli Lilly and Regeneron are both seeking emergency use authorization from the Food and Drug Administration.

Article continues below

The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Peter Weber, The Week US
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.